Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is a Healthcare company (Biotechnology) with a market capitalization of $297M. The Maz Rating grades it against the other companies in its sector.
Kyverna Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.70, Kyverna Therapeutics, Inc. trades at 2.2x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -86.9%, return on invested capital of -98.5% and a free cash flow yield of -50.9%. On the balance sheet: a debt-to-equity ratio of 0.24 and a current ratio of 7.01. Over the past 52 weeks the share price ranged from $4.50 to $13.67, with a beta of 2.13.
Kyverna Therapeutics, Inc. does not currently pay a dividend.
4 Wall Street analyst ratings cover the stock: 4 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Kyverna Therapeutics, Inc. (KYTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 6.14% / 30% · (Cash+Inv) / Mkt Cap (36m) 42.0% / 30% · Interest income / Revenue 168000000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 6.14% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 42.0% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 168000000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 6.14% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 42.0% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 168000000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 10.4% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 92.2% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 168000000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 13.2% / 33.33% · (Cash+ST Inv) / Total Assets 90.0% / 33.33% · (Cash+Recv) / Total Assets 90.0% / 33.33% · Interest income / Revenue 168000000.0% / 5% | Fail |
No. As of September 2026, Kyverna Therapeutics, Inc. (KYTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Kyverna Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 168000000.0% of each dividend: Kyverna Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.